Trial
NCT05689164
A Study to Understand the Long-term Safety and Effects of an Experimental Gene Therapy for Duchenne Muscular Dystrophy.
Phase IIITERMINATEDOTHER/UNKNOWNConfidence: LOW
Sponsor
Pfizer
Collaborators
—
Condition
Duchenne Muscular Dystrophy
Intervention
fordadistrogene movaparvovec
Why stopped
All participants who have received fordadistrogene movaparvovec in any Pfizer study will now be assessed for long-term safety in 1 combined study: C3391003
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2025-10-21